Description: ANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. Its Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The resulting liquid biopsy (blood test) enables the detection and investigation of mutations in the patient's cancer for personalized cancer care. The harvested CTCs have a range of applications, including diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring.
Home Page: angleplc.com
AGL Technical Analysis
Surrey Research Park
Guildford,
GU2 7AF
United Kingdom
Phone:
44 14 8334 3434
Officers
| Name | Title |
|---|---|
| Mr. Andrew David William Newland | Founder, CEO & Exec. Director |
| Mr. Ian Francis Griffiths | CFO, Fin. Director, Company Sec. & Exec. Director |
| Mr. Martin Cooke | Director of Operations & Regulatory Affairs |
| Mr. Andrew John Holder | Head of Investor Relations |
| Mr. Paul Smith | Chief Commercial Officer |
| Dr. Madeline Repollet | Head of Clinical Laboratories |
| Ms. Anne-Sophie Pailhes-Jimenez | Head of R&D - ANGLE Europe Ltd. |
| Mr. Michael O'Brien | Bus. Devel. Director |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.2102 |
| Price-to-Sales TTM: | 112.2849 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 128 |